Neoadjuvant treatment with trastuzumab, pertuzumab and paclitaxel in women with HER2+ non-malignant breast cancer can achieve a high rate of pathological complete response (pCR). A small study of 18 patients in Sydney who were in a position to self-fund the dual anti-HER2 treatment and had definitive surgery found the overall pCR rate was 68%. This ...
Already a member?
Enter your email to keep reading.